Cited by 177Immune cells in cancerImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Myeloid cell heterogeneity in cancer: not a single cell alike

Kiss, Mate, Van Gassen, Sofie, Movahedi, Kiavash, Saeys, Yvan, Laoui, Damya·2018·Cellular Immunology

Abstract

Tumors of various histological origins show abundant infiltration of myeloid cells from early stages of disease progression. These cells have a profound impact on antitumor immunity and influence fundamental processes that underlie malignancy, including neoangiogenesis, sustained cancer cell proliferation, metastasis and therapy resistance. For these reasons, development of therapeutic approaches to deplete or reprogram myeloid cells in cancer is an emerging field of interest. However, knowledge about the heterogeneity of myeloid cells in tumors and their variability between patients and disease stages is still limited. In this review, we summarize the most recent advances in our understanding about how the phenotype of tumor-associated macrophages, monocytes, neutrophils, myeloid-derived suppressor cells and dendritic cells is dictated by their ontogeny, activation status and localization. We also outline major open questions that will only be resolved by applying high-dimensional single-cell technologies and systems biology approaches in the analysis of the tumor microenvironment.

Integrity signals

Registry

Crossref · 10.1016/j.cellimm.2018.02.008

Cites

188 of 188 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Myeloid subsets include CD1C DCs, CLEC9A cells, Langerhans cells, AS DCs, plasmacytoid DCs, and migrating DCs.

    “The remaining subsets were re-clustered into CD1C DCs (CD1C, CLEC10A), CLEC9A cells (CLEC9A, CADM1, XCR1), Langerhans cells (CD207, CD1A, S100B), AS DCs (AXL, IGFBP5, PPP1R14A), plasmacytoid DCs (CLEC4C, IL3RA), and migrating DCs (CCR7, CCL19) (Bronte et al., 2016, Kiss et al., 2018, Villani et al., 2017).”
  • Myeloid subsets include macrophages (CD163, CD68) and MDSCs (S100A8, S100A9, TREM1).

    “clusters high in the monocyte marker CD14, which were further re-clustered into macrophages (CD163, CD68) and MDSCs (S100A8, S100A9, TREM1).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kiss, M., Van Gassen, S., Movahedi, K., Saeys, Y., & Laoui, D.
Affiliations
  • Vrije Universiteit Brussel (BE)
  • Ghent University (BE)
Corresponding author
Laoui, Damya
Venue
Cellular Immunology
Publisher
Elsevier BV
Published
2018-08
Volume
330
Pages
188-201
ISSN
0008-8749 (ISSN-L)
OpenAlex
W2789612591
Cited by
159
References
188
Citations by year
2026: 3 · 2025: 5 · 2024: 14 · 2023: 11 · 2022: 38 · 2021: 23 · 2020: 23 · 2019: 24 · 2018: 18
FWCI
2.25
Type
journal article
Language
en
Open access
closed
Locations
  • Cellular Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • Fonds Wetenschappelijk Onderzoek
  • Agentschap voor Innovatie door Wetenschap en Technologie
  • Innoviris
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
myeloid cell heterogeneity, tumor-associated macrophages, tumor-associated monocytes, tumor-associated neutrophils, myeloid-derived suppressor cells, tumor-associated dendritic cells, tumor microenvironment, antitumor immunity, myeloid cell activation, neoangiogenesis, metastasis, treatment resistance, single-cell technologies
MeSH terms
Animals, Dendritic Cells, Humans, Macrophages, Monocytes, Neoplasms, Neutrophils, Myeloid Cells, Cell Proliferation, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review